Imperial College London
Portrait Picture

DrVesselaVassileva

Faculty of Medicine, Department of Surgery & Cancer

Honorary Research Fellow
 
 
 
//

Contact

 

v.vassileva Website

 
 
//

Location

 

ICTEM buildingHammersmith Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Nunes:2017:10.1039/c7ra04606e,
author = {Nunes, JPM and Vassileva, V and Robinson, E and Morais, M and Smith, MEB and Pedley, RB and Caddick, S and Baker, JR and Chudasama, V},
doi = {10.1039/c7ra04606e},
journal = {RSC Advances},
pages = {24828--24832},
title = {Use of a next generation maleimide in combination with THIOMAB (TM) antibody technology delivers a highly stable, potent and near homogeneous THIOMAB (TM) antibody-drug conjugate (TDC)},
url = {http://dx.doi.org/10.1039/c7ra04606e},
volume = {7},
year = {2017}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - Herein we demonstrate that conjugation of a next generation maleimide (NGM) to engineered cysteines in a THIOMAB™ antibody delivers a THIOMAB™ antibody-drug conjugate (TDC) with a drug loading of ca. 2. This TDC is highly stable in blood serum conditions, selective and potent towards HER2 expressing cell lines and meets the current criteria for optimised antibody-drug conjugates (ADCs).
AU  - Nunes,JPM
AU  - Vassileva,V
AU  - Robinson,E
AU  - Morais,M
AU  - Smith,MEB
AU  - Pedley,RB
AU  - Caddick,S
AU  - Baker,JR
AU  - Chudasama,V
DO  - 10.1039/c7ra04606e
EP  - 24832
PY  - 2017///
SN  - 2046-2069
SP  - 24828
TI  - Use of a next generation maleimide in combination with THIOMAB (TM) antibody technology delivers a highly stable, potent and near homogeneous THIOMAB (TM) antibody-drug conjugate (TDC)
T2  - RSC Advances
UR  - http://dx.doi.org/10.1039/c7ra04606e
UR  - http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000401525700035&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202
UR  - http://hdl.handle.net/10044/1/49555
VL  - 7
ER  -
Download